CorTec, the Freiburg-based neurotech company, has received FDA Breakthrough Device Designation for its Brain Interchange system in stroke motor rehabilitation — the first time the agency has granted the designation to any brain-computer interface for that indication. The announcement, made April 8, places CorTec alongside Neuralink, Synchron, and Blackrock Neurotech as the small group of BCI companies to hold the designation, though each of the others received theirs for communication or paralysis applications rather than motor recovery.
The Breakthrough Device programme gives CorTec more frequent and structured regulatory engagement with the FDA, shortening the path to market for a device class that otherwise faces long and uncertain approval timelines.
The device
Brain Interchange is a fully implantable, wireless, bidirectional BCI. It records cortical neural activity and delivers targeted electrical stimulation in a closed loop — reading the brain’s signals and responding with adaptive stimulation in real time. The goal is to drive neuroplasticity in stroke patients whose motor recovery has stalled after conventional rehabilitation.
CorTec received IDE approval in 2024 and implanted the first patient at Harborview Medical Center in Seattle in July 2025. That patient has shown meaningful recovery of upper-limb motor function after previously plateauing with standard therapy, and the implant has logged over 500 days of continuous signal stability. A second patient was implanted at the same site in February 2026 and is recovering as expected. The trial is led by Jeffrey Ojemann at the University of Washington, with Steven Cramer at UCLA as co-investigator, and is funded by the National Institute of Neurological Disorders and Stroke (NIH award UH3NS121565).
Why stroke
Around nine million ischemic strokes occur globally each year, with 1.7 million in the United States and Europe alone. Eighty per cent of stroke patients experience upper-limb impairment, and half remain permanently disabled despite rehabilitation. Existing BCIs have focused almost entirely on enabling paralysed patients to control cursors, robotic arms, or communication software by decoding motor intent. CorTec’s approach is different: rather than routing around the damage, Brain Interchange attempts to repair it by stimulating the brain’s own recovery mechanisms.
The company published neural data from the first patient in Nature Scientific Data, providing an open dataset for the research community. A separate FDA-registered epilepsy study is also under way at Mayo Clinic, and CorTec lists depression and paralysis as future target indications.
Company background
Founded in 2010, CorTec describes itself as the first European company to bring a fully implantable, bidirectional BCI into FDA-approved clinical evaluation in the United States. The company operates a dual business model: its own Brain Interchange platform alongside a contract development and manufacturing division. Investors include High-Tech Gründerfonds, KfW, LBBW Venture Capital, and several private backers. The device is manufactured entirely in Germany.
CorTec’s regulatory timeline has been methodical: 510(k) clearance for cortical mapping electrodes in 2019, a successful closed-loop stimulation feasibility study in 2023, IDE approval in 2024, and now Breakthrough Device Designation in 2026. The next milestone will be expanding the Harborview trial and generating the longer-term outcome data the FDA will need for eventual clearance.